News & Updates

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

05 Mar 2025 by

The combination of nivolumab and ipilimumab (NIVO + IPI) significantly improves overall survival (OS) and objective response rate (ORR) compared with lenvatinib or sorafenib (LEN/SOR) in the first-line setting for patients with unresectable hepatocellular carcinoma (uHCC), based on the CheckMate 9DW expanded analyses presented at ASCO GI 2025.

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

05 Mar 2025

De-escalating ticagrelor monotherapy reduces bleeding in ACS

04 Mar 2025

De-escalation of dual antiplatelet therapy (DAPT) to ticagrelor monotherapy results in a decreased risk for major bleeding compared with standard DAPT among patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, reports a study.

De-escalating ticagrelor monotherapy reduces bleeding in ACS

04 Mar 2025

MERLIN: Brolucizumab not inferior to aflibercept in nAMD

04 Mar 2025 by

Two-year treatment with brolucizumab 6 mg every 4 weeks demonstrates noninferiority in mean best-corrected visual acuity (BCVA), with superior anatomic outcomes, to aflibercept 2 mg every 4 weeks in patients with neovascular age-related macular degeneration (nAMD), as shown in the MERLIN study.

MERLIN: Brolucizumab not inferior to aflibercept in nAMD

04 Mar 2025

Oestradiol patches bump up ADT armamentarium for prostate cancer

04 Mar 2025 by

Findings from a phase II trial demonstrate the potential of transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT) for men with metastatic (M1) prostate cancer who are on androgen receptor pathway inhibitors (ARPI).

Oestradiol patches bump up ADT armamentarium for prostate cancer

04 Mar 2025

Age does not influence ferric derisomaltose treatment outcomes

03 Mar 2025

In the treatment of patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency, the use of ferric derisomaltose appears to result in similar outcomes across age groups, according to data from the open-label IRONMAN trial.

Age does not influence ferric derisomaltose treatment outcomes

03 Mar 2025

GLP-1RAs lower depression risk in older adults with T2D

03 Mar 2025

The incidence of depression among older adults with type 2 diabetes is low, and the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) helps reduce the risk of depression relative to dipeptidyl peptidase-4 inhibitors (DPP4is), but not sodium–glucose cotransporter-2 inhibitors (SGLT2is).

GLP-1RAs lower depression risk in older adults with T2D

03 Mar 2025

Real-world data support FTD/TPI plus bevacizumab for mCRC

03 Mar 2025 by

A combination regimen comprising trifluridine/tipiracil (FTD/TPI) and bevacizumab demonstrates favourable efficacy and safety in individuals with metastatic colorectal cancer (mCRC) in the real-world BeTAS study presented at ASCO GI 2025.

Real-world data support FTD/TPI plus bevacizumab for mCRC

03 Mar 2025

Can semaglutide curb drinking?

02 Mar 2025 by

The glucagon-like peptide 1 receptor agonist (GLP-1RA) semaglutide has the potential to reduce alcohol cravings and consumption in adults with alcohol use disorder (AUD), as shown in a phase II study.

Can semaglutide curb drinking?

02 Mar 2025

BP-lowering meds help improve hypertension outcomes even in frail individuals

02 Mar 2025

In older adults with hypertension, the presence of frailty does not appear to reduce the effectiveness of antihypertensive treatment, according to a study.

BP-lowering meds help improve hypertension outcomes even in frail individuals

02 Mar 2025

Sotagliflozin: First SGLT inhibitor to show ischaemic benefit

01 Mar 2025

The dual sodium–glucose co-transporter (SGLT) 1/2 inhibitor sotagliflozin appears to reduce the risk of major adverse cardiovascular events (MACE), especially myocardial infarction and stroke—a benefit that has not been previously observed with other drugs of the same class—in patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk, according to the secondary analysis of the SCORED trial.

Sotagliflozin: First SGLT inhibitor to show ischaemic benefit

01 Mar 2025

News & Updates

Filter by Specialty:

Specialty:

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

De-escalating ticagrelor monotherapy reduces bleeding in ACS

De-escalating ticagrelor monotherapy reduces bleeding in ACS

MERLIN: Brolucizumab not inferior to aflibercept in nAMD

MERLIN: Brolucizumab not inferior to aflibercept in nAMD

Oestradiol patches bump up ADT armamentarium for prostate cancer

Oestradiol patches bump up ADT armamentarium for prostate cancer

Age does not influence ferric derisomaltose treatment outcomes

Age does not influence ferric derisomaltose treatment outcomes

GLP-1RAs lower depression risk in older adults with T2D

GLP-1RAs lower depression risk in older adults with T2D

Real-world data support FTD/TPI plus bevacizumab for mCRC

Real-world data support FTD/TPI plus bevacizumab for mCRC

Can semaglutide curb drinking?

Can semaglutide curb drinking?

BP-lowering meds help improve hypertension outcomes even in frail individuals

BP-lowering meds help improve hypertension outcomes even in frail individuals

Sotagliflozin: First SGLT inhibitor to show ischaemic benefit

Sotagliflozin: First SGLT inhibitor to show ischaemic benefit